KalGene Pharma News - LARVOL Sigma

|||||||||| KG207 / KalGene Pharma
PK/PD data, Preclinical, Journal: Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer's Disease in Rat and Dog. (Pubmed Central) - Jul 6, 2022
This study demonstrates translational attributes of BBB-crossing Aβ-targeting biotherapeutic KG207-H in eliciting a pharmacodynamic response, from rodents to larger animal species.

|||||||||| KG207 / KalGene Pharma
Preclinical, Journal: Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. (Pubmed Central) - Apr 14, 2022
Finally, FC5-mFc2a-ABP (referred to as KG207-M) treatment did not induce amyloid-related imaging abnormalities such as microhemorrhage. Together, this study demonstrates the translational values of the designed preclinical studies for the assessment of novel therapies based on the clinical biomarkers providing tangible metrics for designing early-stage clinical trials.



	Diseases Companies Products Productz Mechanisms of Action Sites